Icotrokinra is currently being developed through a licensing and collaboration agreement between Protagonist and J&J.

Medically reviewed by Brendan Camp, MD Many people with psoriasis successfully undergo cosmetic procedures, but they should avoid treatments done directly on psoriasis lesions or during flare-ups ...

Early intervention with IL-17 inhibitors among patients with plaque psoriasis is associated with improved relapse and remission rates.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Sometimes it'll be in the middle of a workday. Other days I'll come in and see plaques and some of the flaking on my suit. And so before our treatment, I would never imagine wearing some dark ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis for up to 52 weeks. ... supporting cost-effective treatment options.

Catching psoriasis early — and getting a formal diagnosis by a medical professional — allows for prompt treatment, possibly slowing the progression of the disease and its impact on your life.

Mark said he had psoriasis covering 90-95% of his body. “I got the stares and the mocking and the name calling,” Mark said. “It was indeed very, very traumatic.” ...